Skip to main content

Table 3 Initial recurrence patterns and treatment for recurrence

From: Prognoses, outcomes, and clinicopathological characteristics of very elderly patients with hepatocellular carcinoma who underwent hepatectomy

 

Group VE (n = 49)

Group E (n = 363)

Group Y (n = 384)

p; VE vs. E

p; VE vs. Y

Recurrence cases (%)

49 (24)

64 (231)

68 (261)

0.04

< 0.01

Median recurrence duration (months) (range)

11 (3–68)

11 (0.4–111)

9 (0.2–197)

0.98

0.39

Recurrence site

(n = 24)

(n = 231)

(n = 261)

  

 Liver (%)

75 (18)

83 (192)

82 (213)

0.32

0.42

 Lung (%)

33 (8)

18 (41)

29 (75)

0.06

0.63

 Adrenal glands (%)

8 (2)

2 (5)

5 (14)

0.07

0.54

 Bone (%)

13 (3)

11 (25)

10 (27)

0.80

0.74

Treatment for recurrence

(n = 24)

(n = 231)

(n = 261)

  

 Rehepatectomy (%)

0 (0)

6 (15)

46 (119)

0.19

< 0.01

 Liver transplantation (%)

0 (0)

0 (0)

3 (8)

-

0.38

 RFA/MCT (%)

33 (8)

25 (57)

18 (46)

0.35

0.06

 TACE (%)

63 (15)

52 (121)

47 (122)

0.34

0.13

 Resection of metastases (%)

13 (3)

3 (7)

5 (13)

0.02

0.12

 Systemic chemotherapy including molecular target drug (%)

17 (4)

23 (53)

33 (85)

0.48

0.10

 Radiation (%)

17 (4)

12 (27)

16 (43)

0.47

0.98

  1. VE very elderly group, E elderly group, Y young group, RFA radiofrequency ablation, MCT microwave coagulation therapy, transcatheter arterial chemoembolization